Benefits of Dexmedetomidine in Management of Post-ECT Agitation.
Electroconvulsive therapy (ECT) is an intervention for patients with a variety of psychiatric conditions. Occasionally, people exhibit dangerous degrees of agitation after this treatment, and some do not respond well to conventional pharmacotherapies. Dexmedetomidine is a central α-2 agonist that can induce significantly calmative effects in persons with post-ECT agitation. The indication for it is in calming individuals with acute and/or recurrent posttreatment agitation. Dexmedetomidine is safe and effective when infused just before, or postictally, at ECT sessions.
From the *University of Minnesota; †Regions Hospital, Minneapolis-St Paul, MN; and ‡University of Louisville School of Medicine, Louisville, KY.
Puneet
P
Narang
Francesca
F
Ianovich
Simrat Kaur
SK
Sarai
Steven
S
Lippmann
D000328:Adult; D000762:Anesthesia Recovery Period; D020927:Dexmedetomidine / Q000627:therapeutic use*; D004351:Drug Resistance; D004565:Electroconvulsive Therapy / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D008297:Male; D011595:Psychomotor Agitation / Q000188:drug therapy* / Q000209:etiology* / Q000523:psychology; D055815:Young Adult
D006993:Hypnotics and Sedatives; D020927:Dexmedetomidine